Logo-bma
Biomed adv. 2025;2(4): 171-172. doi: 10.34172/bma.33

Editorial

Mitochondria refine mesenchymal stem cell-based therapies

Sepideh Zununi Vahed 1 * ORCID

Cited by CrossRef:



Acceptance Rate: 35%
Submission to First Decision: 20 Days
Received to Acceptance: 60 Days
Acceptance to Publication: 40 Days
*Average article statistics from the last 12 months of data.